Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BARRY BERMAN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1578556098
CMS profile
1148570
Location
WEST PALM BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$3,730.07

179 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,205.63 173
Long term medical supply or device loan $398.80 4
Education $125.64 2

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BARRY BERMAN

NPI 1578556098 · CMS profile ID 1148570

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

WEST PALM BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578556098?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BARRY BERMAN, NPI 1578556098, CMS profile ID 1148570. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578556098?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). BARRY BERMAN, NPI 1578556098, CMS profile ID 1148570. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578556098?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
BARRY BERMAN, NPI 1578556098, CMS profile ID 1148570, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1578556098?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

179 matching records · $3,730.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 179 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 179.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $19.9209/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917897845 CMS
Sobi, Inc $13.0108/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940381239 CMS
GENZYME CORPORATION $24.5408/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938760287 CMS
Pharmacyclics LLC, an AbbVie Company $18.0008/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890336903 CMS
Regeneron Healthcare Solutions, Inc. $20.4708/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927107333 CMS
GENZYME CORPORATION $18.5608/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938760285 CMS
AstraZeneca Pharmaceuticals LP $13.6308/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915122378 CMS
AstraZeneca Pharmaceuticals LP $23.4508/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915742587 CMS
AstraZeneca Pharmaceuticals LP $26.6908/17/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915792315 CMS
Bayer HealthCare Pharmaceuticals Inc. $24.4608/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929823681 CMS
Celgene Corporation $24.0408/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932613043 CMS
Genentech USA, Inc. $16.7308/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950704235 CMS
Amgen Inc. $16.5608/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939911169 CMS
E.R. Squibb & Sons, L.L.C. $13.0108/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932612993 CMS
Incyte Corporation $24.1508/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943014397 CMS
Adaptive Biotechnologies Corporation $15.9108/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951438163 CMS
Acrotech Biopharma LLC $14.2508/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937454385 CMS
Celgene Corporation $19.8708/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932612997 CMS
Celgene Corporation $1.0908/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932612999 CMS
Novartis Pharmaceuticals Corporation $4.8608/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893529213 CMS
E.R. Squibb & Sons, L.L.C. $18.2208/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932612995 CMS
Genentech USA, Inc. $26.2807/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950705579 CMS
Seagen Inc. $12.1207/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904115157 CMS
Pharmacyclics LLC, an AbbVie Company $12.3007/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890336901 CMS
Celgene Corporation $1.2507/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932612975 CMS
Celgene Corporation $0.2407/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932612977 CMS
Celgene Corporation $13.3207/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932612979 CMS
PFIZER INC. $17.4207/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949549919 CMS
AstraZeneca Pharmaceuticals LP $16.0307/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915023727 CMS
Novartis Pharmaceuticals Corporation $9.5507/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893529215 CMS
ARRAY BIOPHARMA INC $17.7007/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949544573 CMS
Janssen Biotech, Inc. $16.4507/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885770951 CMS
AstraZeneca Pharmaceuticals LP $23.8207/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915588395 CMS
Celgene Corporation $9.6107/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932612983 CMS
Celgene Corporation $0.4107/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932612985 CMS
Merck Sharp & Dohme LLC $19.0107/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944171251 CMS
AstraZeneca Pharmaceuticals LP $14.2306/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915881115 CMS
Celgene Corporation $16.4406/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932612967 CMS
MorphoSys, US Inc. $17.0806/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962540133 CMS
Genentech USA, Inc. $15.1606/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950714703 CMS
Janssen Biotech, Inc. $16.4306/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885770919 CMS
Merck Sharp & Dohme LLC $12.3806/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944173121 CMS
Novartis Pharmaceuticals Corporation $13.2506/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893529211 CMS
GlaxoSmithKline, LLC. $14.3306/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944495289 CMS
Gilead Sciences, Inc. $23.9006/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929578601 CMS
Novartis Pharmaceuticals Corporation $99.7006/15/2022 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893529227 CMS
E.R. Squibb & Sons, L.L.C. $22.5106/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932612889 CMS
AVEO Pharmaceuticals, Inc. $18.1706/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950102113 CMS
Novartis Pharmaceuticals Corporation $5.5506/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893529207 CMS
G1 Therapeutics, Inc. $21.8806/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954027653 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,679.87 102
PY2020 $6,561.71 117
PY2021 $4,013.03 127
PY2022 $3,730.07 179
PY2023 $4,716.38 215
PY2024 $4,490.61 221
PY2025 $6,560.13 235

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $308,081.78 43
PY2024 Principal investigator $340,319.45 31
PY2023 Principal investigator $477,833.96 84
PY2022 Principal investigator $101,058.43 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738955
Principal investigator 1 Genentech, Inc. $2,800.00 12/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211649995
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738953
Principal investigator 1 Genentech, Inc. $2,800.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211649921
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738951
Principal investigator 1 Aadi Bioscience, Inc. $100.00 10/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946897
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,750.00 10/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line locally advanced or metastatic HER2-expressing Biliary Tract Cancer No dispute reported 06/30/2026 1185537459
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738921
Principal investigator 1 SEAGEN INC. $3,000.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228821061
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738923
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,900.00 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738925
Principal investigator 1 SEAGEN INC. $3,000.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228821034
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738927
Principal investigator 1 Genentech, Inc. $36,950.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211649853
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738929
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,600.00 06/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185537475
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,150.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line locally advanced or metastatic HER2-expressing Biliary Tract Cancer No dispute reported 06/30/2026 1185537463
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738931
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738933
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738935
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738937
Principal investigator 1 AstraZeneca Pharmaceuticals LP $43,385.00 05/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185537473
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,334.25 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185537465
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,750.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185537467
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,266.26 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185537471
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738939
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738941
Principal investigator 1 Mirati Therapeutics, Inc. $2,379.00 04/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530690
Principal investigator 1 SEAGEN INC. $3,000.00 04/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 MULTI COHORT OPEN LABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48 ADC IN SUBJECTS WITH HER2 EXPRESSING LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA No dispute reported 06/30/2026 1228821594
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,125.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738943
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738945
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738947
Principal investigator 1 SEAGEN INC. $3,000.00 03/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228822386
Principal investigator 1 AstraZeneca Pharmaceuticals LP $40,450.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line locally advanced or metastatic HER2-expressing Biliary Tract Cancer No dispute reported 06/30/2026 1185537461
Principal investigator 1 Mirati Therapeutics, Inc. $7,568.62 03/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530698
Principal investigator 1 Aadi Bioscience, Inc. $3,066.36 03/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946895
Principal investigator 1 Aadi Bioscience, Inc. $3,000.00 02/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946893
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,000.00 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738949
Principal investigator 1 SEAGEN INC. $3,000.00 01/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228821919
Principal investigator 1 Amgen Inc. $19,207.29 01/27/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS - EAST
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) No dispute reported 06/30/2026 1246641391
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,700.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185537469
Principal investigator 1 Mirati Therapeutics, Inc. $30,000.00 01/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236530694
Principal investigator 1 SEAGEN INC. $3,000.00 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228822369